EVAX Stock Analysis: Buy, Sell, or Hold?
EVAX - Evaxion A/S American Depositary Share
$3.33
0.02 (0.60%)
▲
5d:
+6.39%
30d:
+12.5%
90d:
-18.38%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 20, 2026
0d
Get Alerted When EVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: EVAX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: EVAX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: EVAX is currently trading at $3.33, which is considered extended relative to its 30-day fair value range of $2.89 to $3.16. The stock's valuation (Forward PE: 82.8) is in line with its historical norms (83.6). Remarkably, the market is currently pricing in an annual earnings decline of 0.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EVAX is in a strong downtrend. Immediate support is located at $2.83, while resistance sits at $3.64.
Market Sentiment: EVAX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.25 (+239.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EVAX is in a strong downtrend. Immediate support is located at $2.83, while resistance sits at $3.64.
Market Sentiment: EVAX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.25 (+239.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.89 -
$3.16
Company Quality Score
32/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
19.0%
All Signals
- BEARISH: Price extended above range (+5.4% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: Trading 239.9% below Wall St target ($11.25)
- WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.89 -
$3.16
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.83
Resistance Level
$3.64
Current Trend
Strong Downtrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
82.75
Wall Street Target
$11.25
(+239.9%)
Revenue Growth (YoY)
-100.0%
Profit Margin
-129.6%
Valuation Discount vs History
-0.3% cheaper
PE vs Historical
82.8 vs 83.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.3%
(market-implied from PE analysis)
1-Year Target
$3.30
(0%)
2-Year Target
$3.29
(-1%)
3-Year Target
$3.28
(-1%)
3-Yr Target (if PE normalizes)
(PE: 83→84)
$3.31
(+0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 82.8 to 83.6
Stabilization Target:
$3.34
(+1.0%)
PE Expansion Potential:
+1.0%
Share & Embed Analysis
Last updated: August 24, 2026 3:04 PM ET
Data refreshes hourly during market hours. Next update: 4:04 PM
Data refreshes hourly during market hours. Next update: 4:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 62 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 37 SELL |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 47 HOLD |